Aminoimidazole carboxamide ribonucleotide ameliorates experimental autoimmune uveitis

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 7, 2012, Pages 4158-4169

  Suzuki, Jun ^a   Yoshimura, Takeru ^b   Simeonova, Marina ^a   Takeuchi, Kimio ^a   Murakami, Yusuke ^a   Morizane, Yuki ^a   Miller, Joan W ^a   Sobrin, Lucia ^a   Vavvas, Demetrios G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; ADENOSINE KINASE INHIBITOR; ADENOSINE PHOSPHATE; AMINOIMIDAZOLE CARBOXAMIDE RIBONUCLEOTIDE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 10; INTERLEUKIN 17; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; MESSENGER RNA; RIBONUCLEOTIDE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; AICA RIBONUCLEOTIDE; ANTIDIABETIC AGENT; CYTOKINE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE UVEITIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EYE INFLAMMATION; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HISTOPATHOLOGY; IMMUNIZATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; WESTERN BLOTTING; ANIMAL; AUTOIMMUNE DISEASE; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; T LYMPHOCYTE; TREATMENT OUTCOME; UVEA; UVEITIS;

AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HYPOGLYCEMIC AGENTS; IMMUNITY, CELLULAR; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; RIBONUCLEOTIDES; T-LYMPHOCYTES; TREATMENT OUTCOME; UVEA; UVEITIS;

EID: 84866291939     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-9323     Document Type: Article

References (48)

1. Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A. Clinical features of Chinese patients with Behcet's disease. Ophthalmology. 2008;115:312-318.
2. Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D, Abu El- Asrar AM. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27:201-210.
3. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88:1159-1162.
4. Lobo A, Barton K, Minassian D, du Bois RM, Lightman S. Visual loss in sarcoid-related uveitis. Clin Exp Ophthalmol. 2003;31: 310-316.
5. Luger D, Caspi RR. New perspectives on effector mechanisms in uveitis. Semin Immunopathol. 2008;30:135-143.
6. Rizzo LV, Silver P, Wiggert B, et al. Establishment and characterization of a murine CD4{thorn} T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice. J Immunol. 1996;156:1654-1660.
7. Sanui H, Redmond TM, Kotake S, et al. Identification of an immunodominant and highly immunopathogenic determinant in the retinal interphotoreceptor retinoid-binding protein (IRBP). J Exp Med. 1989;169:1947-1960.
8. Yoshimura T, Sonoda KH, Miyazaki Y, et al. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol. 2008;20:209-214.
9. Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13:711-718.
10. Jenkins MK. The ups and downs of T cell costimulation. Immunity. 1994;1:443-446.
11. Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell. 1994;76:275-285.
12. Bagenstose LM, Agarwal RK, Silver PB, et al. Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance. J Immunol. 2005;175:124-130.
13. Namba K, Ogasawara K, Kitaichi N, et al. Amelioration of experimental autoimmune uveoretinitis by pretreatment with a pathogenic peptide in liposome and anti-CD40 ligand monoclonal antibody. J Immunol. 2000;165:2962-2969.
14. Fukai T, Okada AA, Sakai J, et al. The role of costimulatory molecules B7-1 and B7-2 in mice with experimental autoimmune uveoretinitis. Graefes Arch Clin Exp Ophthalmol. 1999; 237:928-933.
15. Hardie DG. The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci. 2004;117:5479-5487.
16. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999;277:E1-10.
17. Sag D, Carling D, Stout RD, Suttles J. Adenosine 50-monophosphate- activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol. 2008;181:8633-8641.
18. Krawczyk CM, Holowka T, Sun J, et al. Toll-like receptorinduced changes in glycolytic metabolism regulate dendritic cell activation. Blood. 2010;115:4742-4749.
19. Henin N, Vincent MF, Van den Berghe G. Stimulation of rat liver AMP-activated protein kinase by AMP analogues. Biochim Biophys Acta. 1996;1290:197-203.
20. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I. 5- aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci. 2004;24:479-487.
21. Zhao X, Zmijewski JW, Lorne E, et al. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008;295:L497-504.
22. Prasad R, Giri S, Nath N, Singh I, Singh AK. 5-aminoimidazole- 4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial- monocyte interaction. J Neurosci Res. 2006;84:614-625.
23. Nath N, Giri S, Prasad R, Salem ML, Singh AK, Singh I. 5- aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol. 2005;175:566-574.
24. Suzuki J, Manola A, Murakami Y, et al. Inhibitory effect of aminoimidazole carboxamide ribonucleotide (AICAR) on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci. 2011;52:6565-6571.
25. Jorgensen SB, Viollet B, Andreelli F, et al. Knockout of the alpha2 but not alpha1 50-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. J Biol Chem. 2004;279:1070-1079.
26. Pouvreau I, Zech JC, Thillaye-Goldenberg B, Naud MC, Van Rooijen N, de Kozak Y. Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis. J Neuroimmunol. 1998;86:171-181.
27. Thurau SR, Chan CC, Nussenblatt RB, Caspi RR. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol. 1997;109:370-376.
28. Caspi RR, Roberge FG, Chan CC, et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol. 1988;140:1490-1495.
29. Wang X, Uto T, Sato K, et al. Potent activation of antigenspecific T cells by antigen-loaded nanospheres. Immunol Lett. 2005;98:123-130.
30. Caspi R. Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol Res. 2008;42: 41-50.
31. Sun M, Yang P, Du L, Zhou H, Ren X, Kijlstra A. Contribution of CD4{thorn}CD25{thorn} T cells to the regression phase of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2010; 51:383-389.
32. Keino H, Takeuchi M, Usui Y, et al. Supplementation of CD4{thorn}CD25{thorn} regulatory T cells suppresses experimental autoimmune uveoretinitis. Br J Ophthalmol. 2007;91:105-110.
33. Takeuchi M, Yokoi H, Tsukahara R, Sakai J, Usui M. Differentiation of Th1 and Th2 cells in lymph nodes and spleens of mice during experimental autoimmune uveoretinitis. Jpn J Ophthalmol. 2001;45:463-469.
34. Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol. 2011;23:202-208.
35. Kushwah R, Hu J. Complexity of dendritic cell subsets and their function in the host immune system. Immunology. 2011; 133:409-419.
36. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345-350.
37. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006;203:1685-1691.
38. Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4{thorn} T cells. J Immunol. 1995;154:5071-5079.
39. Mayer A, Denanglaire S, Viollet B, Leo O, Andris F. AMPactivated protein kinase regulates lymphocyte responses to metabolic stress but is largely dispensable for immune cell development and function. Eur J Immunol. 2008;38:948-956.
40. Maciver NJ, Blagih J, Saucillo DC, et al. The liver kinase b1 is a central regulator of T cell development, activation, and metabolism. J Immunol. 2011;187:4187-4198.
41. Hardie DG, Scott JW, Pan DA, Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 2003;546:113-120.
42. Tamas P, Hawley SA, Clarke RG, et al. Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2{thorn} in T lymphocytes. J Exp Med. 2006;203:1665-1670.
43. Labuzek K, Liber S, Gabryel B, Okopien B. AICAR (5- aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) in- creases the production of toxic molecules and affects the profile of cytokines release in LPS-stimulated rat primary microglial cultures. Neurotoxicology. 2010;31:134-146.
44. Qin S, Ni M, De Vries GW. Implication of S-adenosylhomocysteine hydrolase in inhibition of TNF-alpha- and IL-1betainduced expression of inflammatory mediators by AICAR in RPE cells. Invest Ophthalmol Vis Sci. 2008;49:1274-1281.
45. Kuo CL, Ho FM, Chang MY, Prakash E, Lin WW. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 gene expression by 5-aminoimidazole-4- carboxamide riboside is independent of AMP-activated protein kinase. J Cell Biochem. 2008;103:931-940.
46. Jhun BS, Jin Q, Oh YT, et al. 5-Aminoimidazole-4-carboxamide riboside suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of phosphatidylinositol 3- kinase/Akt activation in RAW 264.7 murine macrophages. Biochem Biophys Res Commun. 2004;318:372-380.
47. Mangano DT, Miao Y, Tudor IC, Dietzel C. Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol. 2006; 48:206-214.
48. Cuthbertson DJ, Babraj JA, Mustard KJ, et al. 5-aminoimidazole- 4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes. 2007;56:2078-2084.